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Core evidence outcomes summary for capecitabine in advanced carcinoma of the pancreas

  **Outcome measure**                                                                   **Evidence**   **Implications**
  ------------------------------------------------------------------------------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  **Patient-oriented evidence**                                                                        
  Statistically significant improvement in survival in combination with gemcitabine     Substantial    Capecitabine can be considered as first-line treatment in combination with gemcitabine to prolong survival by a small but significant margin
  Clinical benefit in good PS patients                                                  Moderate       Patients with good PS more likely to benefit from combination chemotherapy
  Acceptable toxicity profile                                                           Substantial    The addition of capecitabine is generally well tolerated
  **Disease-oriented evidence**                                                                        
  Statistically significant response rate improvement in combination with gemcitabine   Substantial    Capecitabine can be administered as first-line treatment in combination with gemcitabine to improve response rates
  **Economic evidence**                                                                                
  Capecitabine adds only drug-acquisition costs to gemcitabine therapy                  Substantial    Minor additional resource implications

PS, performance status.

Scope, aims, and objectives
===========================

Capecitabine (Xeloda^®^, F. Hoffmann-La Roche) is an orally active prodrug of the fluoropyrimidine fluorouracil ([@b34-ce-2-111]; [@b55-ce-2-111]). This review seeks to assess the emerging evidence for capecitabine in the management of carcinoma of the pancreas.

Methods
=======

English language literature searches were conducted on September 25, 2006 in the following databases, searching from the beginning of the database to current date unless otherwise stated. The search strategy was "capecitabine AND pancreatic cancer" unless otherwise stated: PubMed, <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi>, 1966 to date. Limits imposed for specificity: "English," "clinical trial," "meta analysis," "randomized controlled trial," "humans"EMBASE, <http://www.datastarweb.com>BIOSIS, <http://www.datastarweb.com>Database of Abstracts of Reviews of Effects (DARE), National Health Service (NHS) Economic Evaluations Database (NHSEED), Health Technology Assessment (HTA), <http://www.york.ac.uk/inst/crd/crddatabases.htm>. All three databases searched together. All fields searchedNHS HTA, <http://www.ncchta.org>National Guideline Clearinghouse, <http://www.guideline.gov>National Institute for Health and Clinical Excellence (NICE), <http://www.nice.org.uk>Cochrane Database of Systematic Reviews (CDSR), <http://www.cochrane.org/index0.htm>. Entire site searchedClinical Evidence (BMJ), <http://www.clinicalevidence.com>

Online abstracts from the following congresses were searched using the search term "capecitabine": American Society of Clinical Oncology, all conferences from 2000 to 2006, <http://www.asco.org>European Society for Medical Oncology, all conferences from 2003 to 2005, <http://www.esmo.org>European Cancer Conference 2005, <http://ex2.excerptamedica.com/ciw-05ecco>

Following hand searching and removal of duplicates, nonsystematic reviews, editorials, records of study methodology, and pharmacokinetic studies, a total of nine full papers and 16 abstracts were included in the evidence base.

After peer review of the initial submission there was a further search of the abstracts presented at the joint meeting of the International Association of Pancreatology and the American Association of Pancreatology meeting held in November 2006. This identified a further systematic review and meta analysis ([@b53-ce-2-111]). An additional phase II trial was identified via PubMed published in March 2007 ([@b40-ce-2-111]). Since the literature searches were conducted, the study by Moore and colleagues has been published as a full paper ([@b35-ce-2-111]). A summary of the literature search results is shown in [Table 1](#t1-ce-2-111){ref-type="table"}.

Disease overview
================

Adenocarcinoma of the pancreas is one of the main causes of cancer-related death in the western world with about 33 000 new cases annually in the USA ([@b29-ce-2-111]) and 7000 in the UK ([@b39-ce-2-111]). Pancreatic cancer is more common in men (male:female ratio 1.3:1) and is unusual before the age of 45 years but the incidence rises sharply thereafter, reaching a peak in the mid to late 70s. The majority of cases have no obvious genetic predisposition but 5--10% of patients have a first-degree relative with the disease, suggesting some form of familial aggregation ([@b32-ce-2-111]; [@b31-ce-2-111]). The risk of developing pancreatic cancer is increased in a number of familial cancer syndromes ([@b62-ce-2-111]); for example, the lifetime risk in Peutz-Jegher syndrome approaches 36% ([@b22-ce-2-111]; [@b30-ce-2-111]). Patients with hereditary pancreatitis have a 40% chance of developing pancreatic cancer by the age of 70 ([@b27-ce-2-111]) but the risk is lower for sporadic forms of chronic pancreatitis ([@b26-ce-2-111]). Several environmental and lifestyle factors have been implicated in the development of pancreatic cancer including smoking, diet, and body mass index ([@b61-ce-2-111]). Of these the evidence is most conclusive for cigarette smoking with a two-fold increased risk ([@b14-ce-2-111]).

The majority of patients present with painless obstructive jaundice, although upper abdominal and/or back pain, anorexia, and weight loss are also common ([@b1-ce-2-111]). Initial investigations include routine hematology, biochemistry, computed tomography scanning of the chest and abdomen, and serum carcinoembryonic (CA) 19-9 estimation, a tumor marker detectable in a high proportion of patients with pancreatic cancer ([@b6-ce-2-111]). Surgical resection remains the only potentially curative treatment; however, the majority of patients have either locally advanced or metastatic disease at presentation and only around 10% of patients are candidates for pancreatectomy ([@b1-ce-2-111]). The prognosis for patients with pancreatic cancer is poor with an overall survival of 0.4%, median survival of 8 to 12 months for patients with locally advanced disease, and 3 to 6 months for those who present with metastases ([@b5-ce-2-111]). For patients with resectable disease the 5-year survival is around 10% for patients with node-positive disease, and 20--30% for those with node-negative cancers ([@b1-ce-2-111]).

Current therapy options
=======================

Adenocarcinoma of the pancreas is highly resistant to radiotherapy and chemotherapy ([@b53-ce-2-111], [@b54-ce-2-111]; [@b65-ce-2-111]) and although many drugs have been tested in this disease none have consistently demonstrated objective response rates above 10% ([@b51-ce-2-111]). Pancreatic cancer has a highly complex molecular pathology and is uniquely characterized by a high frequency of activating K-ras mutations and loss of function of the p53, p16, and Smad 4 tumor suppresser genes ([@b3-ce-2-111]). A number of altered signaling, DNA repair, and apoptotis pathways may contribute to the resistance of pancreatic cancer to conventional therapies, notably block of the p16/pRb cell cycle control system ([@b41-ce-2-111]). The phosphoinositide 3-OH kinase (PI3K)/Akt pathway, which is frequently amplified or activated in pancreatic cancer, may also contribute to resistance in several ways including the inhibition of proapoptotic proteins BAD and caspase 9 ([@b47-ce-2-111]), dysregulation of the mammalian target of rapamycin (mTOR)-S6K1 signaling pathway ([@b2-ce-2-111]), and activation of the nuclear factor kappa B (NFκB) transcription factor ([@b20-ce-2-111]).

The fluoropyrimidine fluorouracil is used extensively in the treatment of a number of gastrointestinal malignancies including esophageal, gastric, and colorectal cancers, and historically----before the introduction of gemcitabine----was considered to be the most effective available treatment for advanced pancreatic cancer ([@b10-ce-2-111]; [@b51-ce-2-111]). However, more recent trials of fluorouracil with folinic acid (leucovorin) modulation using both infusional and bolus schedules suggest a relatively low response range (0--9%) and a median survival of 10--24 weeks ([@b16-ce-2-111]; [@b18-ce-2-111]; [@b51-ce-2-111]; [@b60-ce-2-111]). The deoxycytidine analog gemcitabine has now replaced fluorouracil as the treatment of choice for advanced pancreatic cancer ([@b8-ce-2-111]) with slightly improved objective response rates (6--11%) in chemotherapy-naïve patients ([@b12-ce-2-111]; [@b9-ce-2-111]) but with superior clinical benefit response ([@b8-ce-2-111]). Clinical benefit response was initially defined in a phase II study of gemcitabine as an improvement in pain (analgesic consumption and pain intensity), Karnofsky Performance Scores (KPS), or weight gain without a deterioration in any other factor even in the absence of an objective response ([@b43-ce-2-111]). In this trial although the objective response rate for patients with measurable disease was only 11%, a clinical benefit was observed in 27%.

In the pivotal trial by [@b8-ce-2-111] both clinical benefit and survival were used as the primary endpoints, where clinical benefit required a sustained (≥4 weeks) improvement in at least one parameter without worsening in any others. One hundred and twenty-six previously untreated patients with locally advanced or metastatic pancreatic cancer were randomized between fluorouracil (600 mg/m^2^ intravenous bolus weekly) or gemcitabine (1000 mg/m^2^ intravenous infusion weekly for 7 weeks followed by a week of rest, then weekly for 3 out of every 4 weeks). Of 56 patients in the gemcitabine arm with bidimensionally measurable disease at study entry, three (5.4%) had a partial response and 22 (39%) had stable disease. Among 57 fluorouracil-treated patients with measurable disease, none had a complete or partial response and 11 (19%) had stable disease. The difference in partial response rates was not statistically significant. Despite the fact that there was no difference in objective response rate between the two groups, gemcitabine was associated with significantly better clinical benefit response (24%) compared with fluorouracil (5%; *P*=0.002). The median survival was 5.7 months for gemcitabine-treated patients and 4.4 months for the fluorouracil-treated patients, with 1-year survival rates of 18% versus 2%, respectively (*P*=0.0025). Criticisms of this study included failure to use a prospectively validated quality-of-life instrument, not using blind treatment assignment for those assessing clinical benefit responses, and comparison with a control arm which employed what is now considered to be a suboptimal method of delivering fluorouracil. Nevertheless, gemcitabine was approved for first-line therapy of metastatic pancreatic cancer and, given its relatively low toxicity, it is now the drug of choice ([@b51-ce-2-111]).

In the adjuvant setting both fluorouracil/leucovorin and single-agent gemcitabine each have been tested in two separate phase III trials called ESPAC-1 and CONKO-001, respectively ([@b37-ce-2-111]; [@b21-ce-2-111]; [@b38-ce-2-111]). Although both regimens produced a similar doubling in 5-year survival rates compared with the control (resection-only) arms, in the case of CONKO-001 the primary endpoint was progression-free survival rather than overall survival as in ESPAC-1 ([@b37-ce-2-111]; [@b21-ce-2-111]; [@b38-ce-2-111]).

A number of groups have investigated other, newer drugs in advanced pancreatic cancer both as single agents and in combination. Studies involving anthracyclines, ifosfamide, taxanes, camptothecins, and platinum analogs have all yielded response rates of less than 10% with no demonstrable improvement in overall survival ([@b51-ce-2-111]). Many combinations have also been tested and although a number of phase II trials have suggested improved response rates for combination chemotherapy, up to now there has been little evidence that these are translated into improved survival ([@b65-ce-2-111]). A systematic review and meta analysis has also demonstrated that chemoradiation followed by chemotherapy does not demonstrate any survival advantage over chemotherapy alone ([@b54-ce-2-111]).

Although a 2006 Cochrane meta analysis concluded that single-agent gemcitabine remained the standard of care ([@b65-ce-2-111]), a more up to date meta analysis indicated that gemcitabine combined with a platinum derivative was indeed superior to gemcitabine alone ([@b53-ce-2-111]).

Moreover, erlotinib, a small molecule tyrosine kinase inhibitor, has also recently been shown to have limited clinical benefit in combination with gemcitabine in the National Canadian Institute of Cancer-led international, multicenter, placebo-controlled phase III trial (PA.3) (Moore et al. 2005). Approximately 75% of the 569 patients randomized had metastatic disease. The overall survival was significantly better in the erlotinib arm compared with the placebo-controlled arm with a median survival of 6.4 versus 5.9 months \[hazard ratio (HR) 0.81; 95% confidence intervals (CI) 0.67, 0.97; *P*=0.025\] and a 1-year survival of 24% versus 17%, respectively. Progression-free survival was also significantly improved with medians of 3.8 versus 3.6 months, respectively (HR 0.76; 95% CI 0.63, 0.91; *P*=0.003). The overall response rate, however, was not different between the two arms (8.6% vs 8.0%, respectively). Toxicity from skin rash and diarrhea was increased in the erlotinib arm although there were no significant differences for global quality-of-life scores (Moore et al. 2005).

In July 2006, the Committee for Medicinal Products for Human Use (CHMP) representing the European Medicines Agency (EMEA) rejected registration of erlotinib because the survival benefit of the combination was very limited. It was concluded that the benefit did not outweigh the risk of side effects, and there was neither improvement in the quality of life nor in progression-free survival and objective response rate ([@b19-ce-2-111]). In December 2006, however, the CHMP recommended the granting of a variation to the marketing authorization for erlotinib for patients with metastatic cancer based on the evidence that there was a 25% improvement in overall survival in this group of patients (but not in patients with locally advanced disease). The Committee also concluded that erlotinib could be prescribed on a patient-by-patient basis, taking into account the chance of survival ([@b19-ce-2-111]).

Unmet needs
===========

The majority of patients with pancreatic cancer will either present with inoperable or metastatic disease or will relapse following resection leading to an overall 5-year survival of \<5% ([@b1-ce-2-111]). Despite the progress made with gemcitabine, systemic therapy is of limited value, with only a small percentage of patients experiencing a short-term benefit usually lasting 4 months or less and the 1-year survival in this group is around 18--20% ([@b8-ce-2-111]). Although there may be improved survival with the combinations of gemcitabine with either erlotinib (Moore et al. 2005) or a platinum derivative ([@b53-ce-2-111]), the absolute improvement in survival is small. The 5-year survival rate following resection alone is about 10%, improving to around 23--29% with adjuvant systemic chemotherapy with either fluorouracil and leucovorin or gemcitabine but most patients relapse soon after ([@b37-ce-2-111]; [@b21-ce-2-111]; [@b38-ce-2-111]). There is therefore an urgent need for new effective treatments to use in this disease both in locally advanced disease and as adjuvant therapy following potentially curative resection.

Clinical evidence with capecitabine in advanced carcinoma of the pancreas
=========================================================================

Fluorouracil is most active and least toxic when delivered using an infusional schedule ([@b33-ce-2-111]) but such treatment either involves a prolonged inpatient stay or the placement of a central line with its attendant risks and inconvenience. Continuous oral dosing can be used to mimic a protracted infusion but this is not possible with fluorouracil because extensive metabolism by dihydropyrimidine dehydrogenase in the mucosa of the gastrointestinal tract and the liver leads to highly variable bioavailability ([@b48-ce-2-111]; [@b55-ce-2-111]).

Capecitabine is a fluorouracil prodrug which was developed in an effort to overcome this problem ([@b34-ce-2-111]). It is absorbed intact through the intestinal wall unaffected by dihydropyrimidine dehydrogenase and then undergoes conversion to fluorouracil in a sequential three-stage enzymatic process ([@b34-ce-2-111]). The final requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor compared with normal tissues, thereby suggesting that fluorouracil delivered in this way may benefit from an element of tumor targeting and thus enhanced selectivity and better tolerability ([@b28-ce-2-111]). Clinical evidence to support this comes from a study in patients with colorectal cancer. Capecitabine was administered 7 days before planned resection of the primary cancer and fluorouracil levels assayed in tumor and adjacent tissues. The median ratio of fluorouracil concentration in colorectal tumors to adjacent tissues was 2.9 (range 0.9--8.0) ([@b50-ce-2-111]). The effectiveness of capecitabine is such that it may replace fluorouracil as the fluoropyrimidine of choice in colorectal ([@b57-ce-2-111]; [@b56-ce-2-111]) and perhaps other cancers as well.

Efficacy
--------

An initial phase II trial of 42 patients with locally advanced or metastatic pancreatic cancer who had received no prior chemotherapy, were treated with standard capecitabine monotherapy (1250 mg/m^2^ twice daily on days 1--14 of a 3-week cycle) in order to investigate safety and efficacy ([@b11-ce-2-111]). The major grade 3/4 adverse events were diarrhea, hand-foot syndrome, and nausea, and overall the safety profile was similar to that of capecitabine in patients with colorectal and breast cancer. Ten (24%) patients achieved a clinical benefit response and 12 (29%) patients had reduced pain intensity. The overall median survival was 6 months with three (7%) partial responses and another 17 (41%) patients with stable disease for a median duration of 2.8 months.

Capecitabine appeared to have definite, albeit limited, activity in advanced pancreatic cancer and it was therefore decided to explore combination treatment with gemcitabine as the next phase of development. This was based on potential synergy between gemcitabine and capecitabine as a result of gemcitabine inhibiting ribonucleotide reductase thus depleting intracellular pools of deoxyuridine monophosphate and leading to enhanced binding of 5-fluorodeoxyuridine monophosphate, the active metabolite of fluorouracil, to thymidylate synthase ([@b42-ce-2-111]) ([Fig. 1](#f1-ce-2-111){ref-type="fig"}).

Phase I/II dose-finding trials were conducted using both 21- and 28-day cycles. An initial study investigated capecitabine in combination with gemcitabine in 36 patients with previously untreated pancreatic cancer ([@b25-ce-2-111]). Escalating doses of capecitabine were administered keeping gemcitabine at a fixed dose of 1000 mg/m^2^ on days 1 and 8. The dose-limiting toxicities were neutropenia and mucositis. A 21-day regimen of capecitabine 650 mg/m^2^ twice daily on days 1--14 in combination with gemcitabine 1000 mg/m^2^ on days 1 and 8 was found to be the most suitable regimen for phase II testing. There was only one grade 4 adverse event in the 12 patients treated at this dose level and there were no cases of diarrhea, hand-foot syndrome, or alopecia in these patients. In patients with evaluable disease the overall response rate was 15%. A second phase I trial in patients with advanced pancreatic cancer determined that capecitabine 880 mg/m^2^ twice daily on days 1--21 of a 28-day cycle with gemcitabine 1000 mg/m^2^ on days 1, 8, and 15 was the most appropriate regimen for further investigation ([@b46-ce-2-111]).

A subsequent phase II trial using a 21-day schedule of gemcitabine 1000 mg/m^2^ on days 1 and 8 plus capecitabine 650 mg/m^2^ on days 1--14 involved 53 patients with advanced pancreatic cancer. There were 10 (18%) partial remissions, 22 patients (42%) with stable disease, and 15 (28%) with progressive disease ([@b52-ce-2-111]). The median time to progression was 6 months, the median survival was 8 months, and 12-month survival was 35%.

Similar results have been reported recently from Korea in a phase II study of 45 patients with advanced pancreatic cancer given gemcitabine combined with dose-escalated 14-day capecitabine as first-line chemotherapy ([@b40-ce-2-111]). Gemcitabine 1000 mg/m^2^ was given on days 1 and 8 plus capecitabine 1000 mg/m^2^ twice daily on days 1--14, in 21-day cycles. The objective response rate was 40% (95% CI 25%, 55%), including one (2%) complete response. The median time to progression was 5.4 months (95% CI 1.8, 9.0) and the median overall survival was 10.4 months (95% CI 6.2, 14.5). Patients with a ≥25% decline of serum CA19-9 had significantly better time to progression and overall survival than those who did not (*P*\<0.03). The most frequent nonhematologic grade 3/4 toxicity was hand-foot syndrome (7%) ([@b40-ce-2-111]).

Following on from the earlier phase I/II studies, the combination of gemcitabine with capecitabine has been compared with gemcitabine alone in one randomized phase II ([@b44-ce-2-111]) and two phase III trials ([@b17-ce-2-111]; [@b24-ce-2-111]) and also in a randomized phase II trial against gemcitabine plus oxaliplatin (GemOx) and capecitabine plus oxaliplatin (XelOx) ([@b23-ce-2-111]).

In the initial randomized phase II study, 83 patients with metastatic pancreatic cancer received either gemcitabine 2200 mg/m^2^ intravenously alone on day 1 with or without capecitabine 2500 mg/m^2^ per day orally on days 1--7 of a 14-day cycle ([@b44-ce-2-111]). The objective response rate for single-agent gemcitabine was 14% compared with 17% for the combination with capecitabine, with median survivals of 8.2 and 9.2 months, respectively. The clinical benefit response was 33% for single-agent gemcitabine and 48% for the combination of gemcitabine with capecitabine. Overall these results support phase III investigation of gemcitabine/capecitabine doublet regimens.

The Swiss Group for Clinical Cancer Research (SAKK) jointly performed a phase III trial with the Central European Cooperative Oncology Group (CECOG) in 319 patients with pancreatic cancer, of whom 79% had metastatic disease ([@b24-ce-2-111]). In the single-agent arm patients were randomized to gemcitabine 1000 mg/m^2^ intravenously on days 1 and 8; patients in the combination arm were randomized to gemcitabine 1000 mg/m^2^ intravenously per week for 2 out of every 3 weeks and capecitabine 1300 mg/m^2^ per day for the first 14 consecutive days every 3 weeks. The median overall survival was 7.3 months for gemcitabine and 8.4 months for the combination arm (*P*=0.314) thus failing to reach the primary endpoint. The response rate was 7.9% for single-agent gemcitabine and 10.1% for the combination arm with a median duration of response of 5.9 versus 7.4 months, respectively. The median time to progression was 4 months for single-agent gemcitabine and 4.8 months for the combination arm. There were 232 patients who were at least 4 weeks on study treatment and therefore evaluable for clinical benefit, of whom 111 (73%) had the combination and 121 (82%) had gemcitabine alone. Overall, 27 (18%) patients with gemcitabine and capecitabine and 29 (20%) patients with single-agent gemcitabine had a clinical benefit response and toxicity was low in both groups ([@b24-ce-2-111]). Cox multivariate analysis found that patients with KPS ≥90 had an improved median survival when treated with the combination arm (10.1 months) compared with single-agent gemcitabine (7.5 months; *P*=0.033) ([@b24-ce-2-111]).

The second phase III trial (GemCap) was organized by the National Cancer Research Institute and Cancer Research UK, with a total of 533 patients randomized to gemcitabine (n=266) or the combination of gemcitabine and capecitabine (n=267) ([@b17-ce-2-111]). Baseline characteristics were well balanced between the gemcitabine and the combination arms ([Table 2](#t2-ce-2-111){ref-type="table"}). Patients randomized to the single-agent arm were scheduled gemcitabine 1000 mg/m^2^ weekly for 7 out every 8 weeks, then 1 week's rest and thereafter weekly for the first 3 of every 4 weeks. The schedule for the combination arm was gemcitabine 1000 mg/m^2^ weekly for the first 3 of every 4 weeks; capecitabine was given at a dose of 1660 mg/m^2^ per day orally for 21 days every 4 weeks followed by 7 days' rest.

Preliminary results were reported following an interim analysis in May 2005, when 373 (70%) deaths had occurred. Grade 3/4 toxicity episodes in the gemcitabine alone and combination arms were anemia (2% vs 1%), neutropenia (11% vs 17%), thrombocytopenia (2% vs 3%), fever (1% vs 0%), diarrhea (1% in both groups), hand-foot syndrome (0% vs 2%), and vomiting (2% vs 1%). In the preliminary analysis grade 3/4 stomatitis had not been reported in either group of patients. The objective response rates were 7% (0 complete responses, 19 partial responses) for gemcitabine alone and 14% (three complete responses, 35 partial responses) for the combination arm (*P*=0.008). Patients randomized to the combination arm had improved overall survival compared with single-agent gemcitabine (HR 0.80; 95% CI 0.65, 0.98; *P*=0.026). The median survival was 6 months for patients receiving gemcitabine alone compared with 7.4 months in the combination arm with 1-year survival rates of 19% and 26%, respectively. After adjusting for baseline stratification factors (stage of disease and performance status), the survival advantage for the patients in the combination arm remained (HR 0.77; 95%CI 0.63, 0.95; *P*=0.014).

A further randomized, phase II study compared capecitabine plus gemcitabine (n=50) with gemcitabine plus oxaliplatin (n=57) and capecitabine plus oxaliplatin (n=54) ([@b23-ce-2-111]). This also showed a trend in favor of the capecitabine-containing arms in terms of response rate and progression-free survival as follows. Patients received 3-week regimens of either capecitabine 2 x 1000 mg/m^2^ daily for 2 weeks plus oxaliplatin 130 mg/m^2^ intravenously on day 1 (CapOx); or capecitabine 2 x 825 mg/m^2^ daily for 2 weeks plus gemcitabine 1000 mg/m^2^ intravenously weekly for 2 weeks (CapGem); or gemcitabine 1000 mg/m^2^ intravenously per week for 2 weeks plus oxaliplatin 130 mg/m^2^ on day 8 (GemOx). Patients in the CapOx, CapGem, and GemOx arms were well balanced with respect to KPS \>70% (89% vs 92% vs 90%, respectively) and stage of disease (metastatic disease in 74% vs 76% vs 75%, respectively). The overall median age was 63 years (range 37--75) and patients received a median of four cycles of treatment. Hematologic grade 3/4 toxicity occurred in 6%, 16%, and 19% for the CapOx vs CapGem vs GemOx groups, respectively; grade 3--4 neurosensoric toxicity was observed in 7%, 0%, and 4%, respectively; while grade 2--3 hand-foot syndrome was found in 9%, 6%, and 2%, respectively. In October 2004, 141 patients were evaluable for response. There were no complete remissions; partial responses were obtained in 22%, 16%, and 13% of the CapOx vs CapGem vs GemOx groups, respectively; and stable disease was reported in 33%, 45%, and 30% respectively. The disease control rates were therefore 55%, 61%, and 43% for the CapOx vs CapGem vs GemOx groups, respectively. The median overall survival for CapOx was 243 days, for CapGem was 229 days, and for GemOx was 241 days (*P*=0.6). The median progression-free survival was 127 days, 143 days, and 91 days for the CapOx vs CapGem vs GemOx groups, respectively ([@b23-ce-2-111]).

Although the SAKK/CECOG trial did not achieve statistical significance for survival, it used a less dose-intense schedule of the gemcitabine/capecitabine combination compared with the UK GemCap trial and it was also comparatively underpowered. Nevertheless, both trials demonstrated similar trends towards improvements in overall survival and response rates. A recent meta analysis has confirmed that the combination of gemcitabine and capecitabine may be superior to single-agent gemcitabine ([@b53-ce-2-111]). Overall, therefore, these preliminary data suggest that the addition of capecitabine to gemcitabine results in a small advantage particularly for patients with good performance status.

There are limited data on second-line chemotherapy in pancreatic cancer and none investigating capecitabine alone following gemcitabine failure. However, the combination of capecitabine plus oxaliplatin has been examined in this group of patients. Oxaliplatin 130 mg/m^2^ on day 1 plus capecitabine 1000 mg/m^2^ twice daily on days 1--14 were administered on a 21-day schedule to 41 patients who had progressed following gemcitabine ([@b64-ce-2-111]). There was one partial response and eight patients with stable disease, with a median survival of 5.8 months and 12-month survival rate of 22%, suggesting at least some activity in this difficult group of patients.

Capecitabine has also been included in studies of chemoradiotherapy in locally advanced carcinoma of the pancreas as an alternative to intravenous fluorouracil and has been shown to be tolerable with predictable toxicity ([@b4-ce-2-111]; [@b15-ce-2-111]). This is a somewhat of a controversial area, however, with little evidence to suggest that chemoradiation adds to systemic chemotherapy in this situation and additional trials are required to define its role ([@b65-ce-2-111]; [@b54-ce-2-111]).

Tolerability
------------

The toxicity of capecitabine itself is relatively noncytotoxic *in vivo* and thus the toxicity profile tends to reflect that of its active metabolite fluorouracil ([@b57-ce-2-111], [@b59-ce-2-111]; [@b45-ce-2-111]; [@b56-ce-2-111]). The toxicity of fluorouracil is dependent on the schedule used. Whereas bolus fluorouracil causes mainly diarrhea, oral mucositis, myelosuppression, and ocular irritation, infusional fluorouracil schedules tend to cause hand-foot syndrome and mucositis, typically comprising inner lip surface ulcers, whereas significant myelosuppression is unusual. The toxicity profile of capecitabine appears to lie somewhere between that of bolus and infusional fluorouracil ([@b7-ce-2-111]) with up to 50% of patients experiencing diarrhea of varying degrees that occasionally may require hospital admission ([@b45-ce-2-111]; [@b56-ce-2-111]). Hand-foot syndrome may occur in around 60% of patients, fatigue is common, and nausea and/or vomiting affects 30% of patients but is readily controlled with antiemetics. Less common side effects include constipation, headaches, conjunctivitis, anorexia, abdominal pain, hair thinning, ankle swelling, and chest pain due to coronary vasospasm ([@b58-ce-2-111]). The use of capecitabine in patients with impaired renal function should be cautious, requiring a 25% dose reduction for those with a creatinine clearance of 30--49 mL/min and should be discontinued if the clearance falls significantly during therapy until recovery occurs. Patients may receive the drug safely despite markedly abnormal liver function since capecitabine does not undergo significant hepatic metabolism ([@b49-ce-2-111]) but administration in such cases should be cautious as such patients are likely to have advanced disease and a poor performance status with little prospect of an effective benefit.

When capecitabine is used in combination, such as with gemcitabine, the dose-limiting toxicity is myelosuppression and thus the dose of capecitabine needs to be attenuated to allow full-dose gemcitabine to be delivered ([@b46-ce-2-111]). The result is a reduction in the incidence of diarrhea and hand-foot syndrome in combination schedules such as in the UK GemCap trial where the incidence of grade 3/4 hand-foot syndrome was 2%, grade 3/4 diarrhea was 1%, and serious stomatitis was not a problem ([@b17-ce-2-111]).

Economic evidence
=================

There are as yet no studies that include an economic evaluation of capecitabine in pancreatic cancer. However, studies have been undertaken in colorectal cancer comparing oral capecitabine with intravenous fluorouracil delivered using either bolus or infusional schedules ([@b63-ce-2-111]; [@b13-ce-2-111]). The data show that while drug acquisition costs are somewhat higher for capecitabine, the costs of managing toxicity are broadly similar and the cost of delivering capecitabine is significantly less than that of fluorouracil due to considerable savings in pharmacy and chemotherapy nursing resources. In addition, the use of capecitabine allows considerable reduction in patient travel costs, and time spent in hospital. Overall, when compared with fluorouracil, capecitabine results in 57% lower chemotherapy-related costs and is therefore a cost-effective option when used as a single agent in colon cancer. In pancreatic cancer the addition of capecitabine to gemcitabine adds little in terms of administration costs, and with reduced capecitabine toxicity in combination regimens, minimal additional resources are needed to manage side effects. The main additional costs therefore relate to drug acquisition, and individual health economies must decide whether or not the modest increase in survival justifies this outlay.

Patient group/population
========================

Performance status is the most important determinant of likelihood of response to chemotherapy in the common solid tumors and pancreatic cancer is no exception. This was highlighted in the SAKK/CECOG study outlined above where a subgroup analysis showed a significantly improved median survival with capecitabine for patients with KPS ≥90% ([@b24-ce-2-111]). Thus patients with few symptoms and a World Health Organization performance status of 0--1 are more likely to benefit from palliative chemotherapy and to tolerate treatment without undue toxicity. Patients with a performance status of 3 are most unlikely to benefit, and for these patients chemotherapy frequently results in unacceptable toxicity. A performance status of 2 tends to encompass quite a broad spectrum with some patients being reasonably fit and well enough for a trial of chemotherapy while others, closer to a performance status of 3, are best served by best supportive care.

Clinical potential
==================

Capecitabine (Xeloda) is an oral prodrug which is converted to fluorouracil by three sequential enzymatic reactions ([@b55-ce-2-111]). The final requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumors compared with normal tissues ([@b34-ce-2-111]; [@b36-ce-2-111]), thereby suggesting that fluorouracil delivered in this way may benefit from an element of tumor targeting and thus enhanced selectivity and better tolerability ([@b28-ce-2-111]; [@b50-ce-2-111]). Fluorouracil is known to be most effective when administered as a protracted infusion but such schedules require indwelling catheters and in pancreatic cancer these cause particular problems with venous thromboembolism. Capecitabine may therefore represent an attractive option since continuous daily dosing can mimic a protracted venous infusion and avoids the need for central lines. Capecitabine has been shown to have modest single-agent activity in advanced carcinoma of the pancreas and when used in combination with gemcitabine may provide a small but significant improvement in response rates and survival compared with gemcitabine alone. These advantages may be most marked in patients with a good performance status and it is in this group where combination treatment including capecitabine is most likely to be of value.

Publication of the final results of both the SAKK/CECOG ([@b24-ce-2-111]) and GemCap phase III ([@b17-ce-2-111]) trials in advanced pancreatic cancer are needed before more certain conclusions can be drawn as to the role of capecitabine in conjunction with gemcitabine in advanced pancreatic cancer.
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###### 

Evidence base included in the review

  **Category**                    **Number of records**   
  ------------------------------- ----------------------- -----
  Initial search                  10                      102
    records excluded              1                       86
    records included              9                       16
  Additional studies identified   0                       1
  Total records included          9                       17
  Level 1 clinical evidence       0                       1
  Level 2 clinical evidence       1                       4
  Level ≥3 clinical evidence                              
    trials other than RCT         8                       11
    case reports                  0                       1
  Economic evidence               0                       0

For definitions of levels of evidence, see Editorial Information on inside back cover.

RCT, randomized controlled trial.

###### 

National Cancer Research Institute/Cancer Research UK GemCap trial: patient characteristics and preliminary results

                                **Gemcitabine**   **Gemcitabine + capecitabine**
  ----------------------------- ----------------- ---------------------------------------------
  Patients                      266               267
  Median age (years)            62                62
  Stage                                           
    metastatic (%)              71                70
    locally advanced (%)        29                30
  Performance status 0--1 (%)   82                81
  Response rate (%)             7                 14[\*](#tfn3-ce-2-111){ref-type="table-fn"}
  Median survival (months)      6.0               7.4
  1-year survival (%)           19                26

*P*=0.026.
